Blueberries Medical Corp. (OTC: BBRRF) generates frequent news as a Latin American licensed producer of medicinal cannabis and cannabis-derived products. Company announcements focus on its operations in the Bogotá Savannah of central Colombia, where it is licensed for the cultivation, production, domestic distribution, and international export of CBD- and THC-based medical cannabis.
News updates often cover financing activities, including non-brokered private placements led by Terraflos Inc. These releases describe how capital is allocated, such as repaying debt, funding operations, and supporting manufacturing and commercial expansion. Early warning disclosures related to Terraflos’ ownership position are a recurring element in these communications.
Another major theme in Blueberries’ news flow is its operational and financial performance. The company regularly reports quarterly and annual financial results, highlighting revenue from CBD and THC derivatives, extraction services, and isolated products. These reports also discuss cost management, shifts in operating expenses, and changes in general and administrative spending.
Investors following BBRRF can also expect updates on market expansion and partnerships. Releases have detailed exports of isolates and derivatives to countries such as Argentina, Peru, and Australia, as well as agreements with Colombian cultivators, joint ventures with other cannabis operators, and collaborations with pharmaceutical and cosmetic laboratories in Latin America.
For those tracking the medicinal cannabis sector, the Blueberries Medical news feed offers ongoing insight into how the company responds to regulatory developments in Colombia, adjusts its business model toward extraction and derivatives, and pursues opportunities in regional and international markets.
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) has reported its 2020 financial results, indicating revenues of $65,978 from commercial cannabis operations after commencing sales in late Q2 2020. Despite significant cost-saving measures, the net loss narrowed to $4,940,107 from $10,787,876 in 2019. The company has focused on cash management, processing capabilities, and establishing sales growth amidst COVID-19 disruptions. Total assets decreased to $7,270,212 while total liabilities rose to $3,380,433.
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) has announced a strategic agreement with Futura Farms to supply 200 kg of premium cannabis oil to Peru, marking its first entry into this market. Peru's medical cannabis market is projected to be worth US$99 million, and this partnership aligns with Blueberries' growth strategy across Latin America, including Colombia and the USA. The agreement is intended to cater to licensed pharmaceutical establishments compliant with Peru's Good Storage Practices. Both companies aim to enhance the quality of medical cannabis treatments in the region.
Blueberries Medical Corp. (CSE: BBM, OTC: BBRRF) has appointed José María Forero as President of Latin American Operations, effective February 16, 2021. Forero, with over 17 years of experience, previously served as Global Head of B2B at Clever Leaves. His expertise in sales and international operations aims to enhance Blueberries' global growth strategy. The company is well-positioned to meet rising demand with its advanced extraction facility and cultivation capacity in Colombia and Argentina. Blueberries is committed to becoming a key player in the international cannabis market.